市場調査レポート

商品コード

1446434

がん支持療法薬市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Cancer Supportive Care Drugs Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年01月30日 | 発行: Allied Market Research

| ページ情報: 英文 338 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,840 603,417円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 6,090 956,982円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,500 1,649,970円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Cancer Supportive Care Drugs Market-IMG1

がん支持療法薬を牽引する主な要因には、がんの有病率の上昇や、化学療法による貧血、吐き気、嘔吐などの抗がん剤使用に伴う副作用があります。

例えば、2022年2月、世界保健機関（WHO）は、世界中で毎年約40万人の小児ががんを発症していると推定しています。また、2022年4月に米国立生物工学情報センター（NCBI）が実施した調査では、乳がん患者における貧血の発生率は約41.1％と推定されました。したがって、がんの有病率の上昇が市場の成長を牽引しています。

さらに、高齢者はがんを発症する可能性が高いため、さまざまな副作用を治療するためのがんサポートケア薬の需要がさらに高まっています。例えば、2022年10月、世界保健機関（WHO）は、60歳以上の世界人口が2050年までに倍増して21億人に達すると推定しています。さらに、米国国立生物工学情報センター（NCBI）によると、高齢者はがん治療の結果として貧血を経験すると予想されています。さらに、がん治療によって引き起こされる副作用に対する患者やヘルスケア専門家の意識の高まりが、がんサポートケア薬への嗜好の上昇につながっています。

さらに、がん治療によって引き起こされる副作用に対する患者およびヘルスケア専門家双方の意識の高まりが、がん支持療法薬への嗜好を高めています。加えて、がん治療中の患者のQOL向上への注目の高まりが、効果的なソリューションへの需要を後押ししています。がんの罹患率が特に小児や高齢者といった特定の層で上昇を続ける中、支持療法薬の需要は持続的な伸びを示すと予測され、包括的ながん治療における極めて重要な役割を裏付けています。

がん支持療法薬市場は、市場の詳細な評価を提供するために、タイプ、用途、流通チャネル、地域に基づいてセグメント化されています。タイプ別では、赤血球造血刺激因子（ESA）、顆粒球コロニー刺激因子（G-CSF）、制吐剤、ビスホスホネート、オピオイド、NSAIDs（非ステロイド性抗炎症薬）、その他に区分されます。用途別では、乳がん、肺がん、大腸がん、前立腺がん、肝臓がん、胃がん、その他に分類されます。流通チャネル別では、病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダーに細分化されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋地域（中国、日本、インド、オーストラリア、韓国、その他アジア太平洋地域）、南米地域（ブラジル、サウジアラビア、アフリカ、その他南米地域）で分析されます。

利害関係者にとっての主なメリット

当レポートは、2022年から2032年までのがん支持療法薬市場分析の市場セグメント、現在の動向、推定・力学の定量的分析を提供し、がん支持療法薬市場の有力な市場機会を特定します。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
がん支持療法薬の市場セグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
本レポートには、地域別および世界のがん支持療法薬の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なレポートカスタマイズ

国、地域、世界レベルでの患者／疫学データ
規制ガイドライン
クライアントの関心に応じた追加企業プロファイル
国別または地域別の追加分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
SWOT分析

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 老人人口の増加
  - がんの有病率の上昇と抗がん剤使用に伴う副作用の増加。
  - がん支持療法薬の採用増加。
- 抑制要因
  - がんの標的療法の進歩
- 機会
  - がん支持療法薬の研究開発およびパイプライン数の増加

第4章がん支持療法薬市場：タイプ別

概要
赤血球造血刺激因子製剤
顆粒球コロニー刺激因子
制吐剤
ビスフォスフォネート
オピオイド
非ステロイド性抗炎症薬
その他

第5章がん支持療法薬市場：用途別

概要
乳がん
肺がん
大腸がん
前立腺がん
肝臓がん
胃がん
その他

第6章がん支持療法薬市場：流通チャネル別

概要
病院薬局
ドラッグストアおよび小売薬局
オンラインプロバイダー

第7章がん支持療法薬市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Novartis AG
Johnson & Johnson
Amgen Inc.
Baxter International Inc.
F. Hoffmann-La Roche AG
Helsinn Healthcare SA
Heron Therapeutics, Inc.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. CANCER SUPPORTIVE CARE DRUGS MARKET FOR ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CANCER SUPPORTIVE CARE DRUGS MARKET FOR GRANULOCYTE COLONY STIMULATING FACTORS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CANCER SUPPORTIVE CARE DRUGS MARKET FOR ANTIEMETICS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. CANCER SUPPORTIVE CARE DRUGS MARKET FOR BISPHOSPHONATES, BY REGION, 2022-2032 ($MILLION)
TABLE 06. CANCER SUPPORTIVE CARE DRUGS MARKET FOR OPIOIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. CANCER SUPPORTIVE CARE DRUGS MARKET FOR NONSTEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 10. CANCER SUPPORTIVE CARE DRUGS MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 11. CANCER SUPPORTIVE CARE DRUGS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 12. CANCER SUPPORTIVE CARE DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 13. CANCER SUPPORTIVE CARE DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 14. CANCER SUPPORTIVE CARE DRUGS MARKET FOR LIVER CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 15. CANCER SUPPORTIVE CARE DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 16. CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. CANCER SUPPORTIVE CARE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 19. CANCER SUPPORTIVE CARE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 20. CANCER SUPPORTIVE CARE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 26. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 33. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 36. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 39. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. UK CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. UK CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. UK CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 58. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 61. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 62. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 65. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 71. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 74. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 80. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 83. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 87. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 90. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 91. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 92. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 94. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 95. NOVARTIS AG: KEY EXECUTIVES
TABLE 96. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 97. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 98. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 99. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 100. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 101. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 102. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 103. AMGEN INC.: KEY EXECUTIVES
TABLE 104. AMGEN INC.: COMPANY SNAPSHOT
TABLE 105. AMGEN INC.: PRODUCT SEGMENTS
TABLE 106. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 107. AMGEN INC.: KEY STRATERGIES
TABLE 108. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
TABLE 109. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 110. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
TABLE 111. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 112. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 113. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 114. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
TABLE 115. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 116. HELSINN HEALTHCARE SA: KEY EXECUTIVES
TABLE 117. HELSINN HEALTHCARE SA: COMPANY SNAPSHOT
TABLE 118. HELSINN HEALTHCARE SA: PRODUCT SEGMENTS
TABLE 119. HELSINN HEALTHCARE SA: PRODUCT PORTFOLIO
TABLE 120. HELSINN HEALTHCARE SA: KEY STRATERGIES
TABLE 121. HERON THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 122. HERON THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 123. HERON THERAPEUTICS, INC.: PRODUCT SEGMENTS
TABLE 124. HERON THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 125. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 126. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 127. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 128. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 129. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 130. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 131. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 132. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 133. PFIZER INC.: KEY EXECUTIVES
TABLE 134. PFIZER INC.: COMPANY SNAPSHOT
TABLE 135. PFIZER INC.: PRODUCT SEGMENTS
TABLE 136. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 137. PFIZER INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF CANCER SUPPORTIVE CARE DRUGS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN CANCER SUPPORTIVE CARE DRUGS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN CANCER SUPPORTIVE CARE DRUGS MARKET (2023-2032)
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. HIGH BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR GRANULOCYTE COLONY STIMULATING FACTORS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR ANTIEMETICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR BISPHOSPHONATES, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR OPIOIDS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR NONSTEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR BREAST CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR LIVER CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 31. CANCER SUPPORTIVE CARE DRUGS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 32. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. UK CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 42. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 43. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 44. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 45. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 46. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 47. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 48. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 49. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 50. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 51. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 54. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 55. COMPETITIVE DASHBOARD
FIGURE 56. COMPETITIVE HEATMAP: CANCER SUPPORTIVE CARE DRUGS MARKET
FIGURE 57. TOP PLAYER POSITIONING, 2022
FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 65. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 68. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 69. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 71. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 72. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 73. HERON THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 74. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 76. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 77. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 78. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 79. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 80. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 81. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 82. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A07133

The main factors that drive the cancer supportive care drugs include rise in prevalence of cancer and adverse effects associated with the use of cancer drugs such as chemotherapy-induced anemia, nausea and vomiting. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated that the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market.

In addition, older people are more likely to develop cancer, which further fuels the demand for cancer support care drugs to treat various side effects. For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are expected to experience anemia as a result of cancer treatment. Furthermore, increase in awareness among patients and healthcare professionals about the side effects cause by cancer treatments has led to an increase in preference for cancer support care drugs.

Moreover, growing awareness among both patients and healthcare professionals about the side effects induced by cancer treatments has driven a preference for cancer supportive care drugs. In addition, the growth in focus on enhancing patients' quality of life during cancer therapy drives the demand for effective solutions. As cancer prevalence continues to rise, particularly among specific demographics such as children and older adults, the demand for supportive care drugs is projected to witness sustained growth, underlining their pivotal role in comprehensive cancer care.

The cancer supportive care drugs market is segmented on the basis of type, application, distribution channel, and region to provide a detailed assessment of the market. By type, it is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (non-steroidal anti-inflammatory drugs), and others. On the basis of application, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer and others. Depending on distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major key players that operate in the global cancer supportive care drugs market are Novartis AG, Johnson & Johnson, Amgen Inc., Baxter International Inc., F. Hoffmann-La Roche AG, Helsinn Healthcare SA, Heron Therapeutics, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Pfizer Inc. The key players have adopted strategies such as agreement and product approval to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer supportive care drugs market analysis from 2022 to 2032 to identify the prevailing cancer supportive care drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the cancer supportive care drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global cancer supportive care drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Type

Erythropoiesis Stimulating Agents
Granulocyte Colony Stimulating Factors
Antiemetics
Bisphosphonates
Opioids
Nonsteroidal Anti Inflammatory Drugs
Others

By Application

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Stomach Cancer
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Novartis AG
Amgen Inc.
Heron Therapeutics, Inc.
Merck & Co., Inc.
Helsinn Healthcare SA
Pfizer Inc.
Baxter International Inc.
Johnson & Johnson
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. High bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Growth in geriatric population
  - 3.4.1.2. Rise in prevalence of cancer and adverse effects associated with use of cancer drugs.
  - 3.4.1.3. Increase in adoption of cancer supportive care drugs.
- 3.4.2. Restraints
  - 3.4.2.1. Advancements in targeted therapy for cancer
- 3.4.3. Opportunities
  - 3.4.3.1. Increase in R&D and number of pipeline cancer supportive care drugs

CHAPTER 4: CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Erythropoiesis Stimulating Agents
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Granulocyte Colony Stimulating Factors
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Antiemetics
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Bisphosphonates
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Opioids
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
4.7. Nonsteroidal Anti Inflammatory Drugs
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
4.8. Others
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country

CHAPTER 5: CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Breast Cancer
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Lung Cancer
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Colorectal Cancer
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Prostate Cancer
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Liver Cancer
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Stomach Cancer
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country
5.8. Others
- 5.8.1. Key market trends, growth factors and opportunities
- 5.8.2. Market size and forecast, by region
- 5.8.3. Market share analysis by country

CHAPTER 6: CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Novartis AG
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Johnson & Johnson
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Amgen Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Baxter International Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. F. Hoffmann-La Roche AG
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Helsinn Healthcare SA
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Key strategic moves and developments
9.7. Heron Therapeutics, Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Merck & Co., Inc.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Pfizer Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

がん支持療法薬市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Cancer Supportive Care Drugs Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章がん支持療法薬市場：タイプ別

第5章がん支持療法薬市場：用途別

第6章がん支持療法薬市場：流通チャネル別

第7章がん支持療法薬市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE

CHAPTER 5: CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION

CHAPTER 6: CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

がん支持療法薬市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Cancer Supportive Care Drugs Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 がん支持療法薬市場：タイプ別

第5章 がん支持療法薬市場：用途別

第6章 がん支持療法薬市場：流通チャネル別

第7章 がん支持療法薬市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE

CHAPTER 5: CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION

CHAPTER 6: CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章がん支持療法薬市場：タイプ別

第5章がん支持療法薬市場：用途別

第6章がん支持療法薬市場：流通チャネル別

第7章がん支持療法薬市場：地域別

第8章競争情勢

第9章企業プロファイル